ANI Pharmaceuticals (ANIP) Projected to Post Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is anticipated to release its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect ANI Pharmaceuticals to post earnings of $2.02 per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:00 AM ET.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $78.10 on Friday. The firm has a market cap of $1.75 billion, a PE ratio of 47.91 and a beta of 0.50. ANI Pharmaceuticals has a 52 week low of $54.10 and a 52 week high of $99.50. The firm’s fifty day moving average is $80.87 and its 200-day moving average is $86.24. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58.

Analyst Ratings Changes

ANIP has been the topic of a number of analyst reports. Guggenheim lifted their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Finally, Barclays initiated coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $103.43.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total value of $42,165.00. Following the transaction, the vice president directly owned 74,374 shares in the company, valued at $6,271,959.42. The trade was a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Renee P. Tannenbaum sold 1,800 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the sale, the director owned 25,157 shares of the company’s stock, valued at $2,041,490.55. This represents a 6.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 4,322 shares of company stock valued at $354,816. 11.10% of the stock is owned by company insiders.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently made changes to their positions in ANIP. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals in the first quarter worth about $28,000. Kemnay Advisory Services Inc. purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $48,000. State of Wyoming bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth $50,000. Tower Research Capital LLC TRC raised its holdings in ANI Pharmaceuticals by 542.0% in the second quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock worth $113,000 after purchasing an additional 1,458 shares in the last quarter. Finally, Vestcor Inc purchased a new stake in shares of ANI Pharmaceuticals during the third quarter valued at about $213,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.